Want to see IN:ALPA full AI Analyst Report?
ALPA Stock Chart & Stats
₹75.60
-₹1.63(-1.24%)
At close: 4:00 PM EST
₹75.60
-₹1.63(-1.24%)
Day’s Range― - ―
52-Week Range₹46.00 - ₹99.75
Previous CloseN/A
Volume65.27K
Average Volume (3M)7.79K
Market Cap
₹1.19B
Enterprise Value-₹380.61M
Total Cash (Recent Filing)₹1.38B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)33.9
Beta1.61
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.68
Shares Outstanding21,040,600
10 Day Avg. Volume12,692
30 Day Avg. Volume7,793
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)0.52
Price to Sales (P/S)0.92
P/FCF Ratio11.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage gives Alpa Laboratories financial resilience and reduces the burden of interest and refinancing obligations. Steadily rising equity also indicates accumulated capital and provides a stronger base to support assets, operations, and future investment through changing business conditions.
Improved Recent Cash GenerationPositive operating cash flow and a return to positive free cash flow in 2026 show that the business can generate cash internally, even though conversion remains incomplete. This supports ongoing operations and gives management greater flexibility than a model dependent on external financing.
Historically Solid Returns On EquityReturns on equity remained solid for the industry context across several years, indicating that Alpa Laboratories has generally converted its shareholder capital into profits. Although the 2026 decline signals pressure, this history provides evidence of an established earnings-generating capability.
Bears Say
Inconsistent Revenue GrowthThe latest revenue contraction, following uneven growth in prior years, makes demand and sales expansion less predictable. A pharmaceutical manufacturer with inconsistent top-line performance may have less reliable operating leverage and a weaker basis for planning capacity, investment, and sustainable earnings growth.
Severe Operating Margin CompressionThe sharp reduction in gross and operating margins indicates substantial deterioration in core operating profitability. An EBIT margin near 1% leaves little buffer against further cost or pricing pressure, and sustained compression could limit reinvestment capacity and weaken the durability of reported earnings.
Weak Earnings-to-cash ConversionOperating cash flow converting only a small portion of reported net income raises concerns about earnings quality and cash realization. The history of negative free cash flow also shows that cash availability can vary materially, increasing uncertainty around internally funded growth and capital allocation.
Alpa Laboratories Limited News
ALPA FAQ
What was Alpa Laboratories Limited’s price range in the past 12 months?
Alpa Laboratories Limited lowest stock price was ₹46.00 and its highest was ₹99.75 in the past 12 months.
What is Alpa Laboratories Limited’s market cap?
Alpa Laboratories Limited’s market cap is ₹1.19B.
When is Alpa Laboratories Limited’s upcoming earnings report date?
Alpa Laboratories Limited’s upcoming earnings report date is Nov 12, 2026 which is in 31 days.
How were Alpa Laboratories Limited’s earnings last quarter?
Alpa Laboratories Limited released its earnings results on Aug 13, 2026. The company reported ₹0.466 earnings per share for the quarter.
Is Alpa Laboratories Limited overvalued?
According to Wall Street analysts Alpa Laboratories Limited’s price is currently Overvalued.
Does Alpa Laboratories Limited pay dividends?
Alpa Laboratories Limited does not currently pay dividends.
What is Alpa Laboratories Limited’s EPS estimate?
Alpa Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alpa Laboratories Limited have?
Alpa Laboratories Limited has 21,040,600 shares outstanding.
What happened to Alpa Laboratories Limited’s price movement after its last earnings report?
Alpa Laboratories Limited reported an EPS of ₹0.466 in its last earnings report. Following the earnings report the stock price went down -0.537%.
Which hedge fund is a major shareholder of Alpa Laboratories Limited?
Currently, no hedge funds are holding shares in IN:ALPA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alpa Laboratories Limited
Established in Indore, India in 1967, Alpa Laboratories Limited focuses on the manufacturing, marketing, and distribution of finished pharmaceutical products, both domestically within India and for export. The company offers a wide array of human-grade medications, encompassing ethical, generic, and over-the-counter varieties, available in diverse forms such as injections, tablets, capsules, eye and ear drops, ointments, creams, and gels. Furthermore, it supplies veterinary pharmaceuticals, including boluses, injections, and intra-mammary infusions. Its extensive product range addresses numerous therapeutic categories, including anti-infectives (covering antibacterials, antibiotics, antifungals, antiprotozoals, and antivirals), pain relievers, anti-inflammatory drugs, cold and cough remedies, cardiovascular treatments, anti-diabetic agents, nutritional supplements, psychotropic medicines, and specialized preparations for skin, ear, and eye care. Alpa Laboratories distributes its goods through a robust network comprising distributors, retail pharmacies, and hospitals. The company also extends its reach internationally, exporting its products to various regions across South and Central America, Africa, Asia, and the CIS countries.
Technical Analysis
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
Brooks Laboratories Limited
―
Nectar Lifesciences Ltd.
―
Par Drugs and Chemicals Limited
―